@article{lundqvist2021killer author = {Björn Lundqvist}, title = {Killer Acquisitions and Other Forms of Anticompetitive Collaborations (Part I):}, journal = {European Competition and Regulatory Law Review}, volume = {5}, number = {3}, year = {2021}, keywords = {pharmaceutical;mergers;antitrust;killer acquisitions}, abstract = {The article aims to address the problem of so-called killer acquisitions broadly, extending also to strategic alliances and other forms of collaborations. We find that ‘killer situations’ can appear in all forms of collaborations that imply a change of control of research results. We therefore conclude in this part I that for the Competition Authority to only focus on killer acquisitions in the form of mergers can be counterproductive. Both mergers and strategic alliances in the pharmaceutical industry would instead benefit from a more intense competition law scrutiny, and in part II we develop what is needed to intensify the competition law scrutiny of accquisitions and collaborations. Keywords: pharmaceutical, mergers, antitrust, killer acquisitions}, url = {https://doi.org/10.21552/core/2021/3/4} doi = {10.21552/core/2021/3/4} }